MX2019015841A - Celulas inmunes defectuosas para suv39h1. - Google Patents

Celulas inmunes defectuosas para suv39h1.

Info

Publication number
MX2019015841A
MX2019015841A MX2019015841A MX2019015841A MX2019015841A MX 2019015841 A MX2019015841 A MX 2019015841A MX 2019015841 A MX2019015841 A MX 2019015841A MX 2019015841 A MX2019015841 A MX 2019015841A MX 2019015841 A MX2019015841 A MX 2019015841A
Authority
MX
Mexico
Prior art keywords
immune cell
suv39h1
immune cells
genetically engineered
engineered
Prior art date
Application number
MX2019015841A
Other languages
English (en)
Inventor
Eliane Piaggio
Sebastian Amigorena
Christel Goudot
Luigia Pace
Geneviève Almouzni
Original Assignee
Inst Curie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Curie filed Critical Inst Curie
Publication of MX2019015841A publication Critical patent/MX2019015841A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4613—Natural-killer cells [NK or NK-T]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Abstract

La presente invención se relaciona con una célula inmune diseñada defectuosa para Suv39h1; preferiblemente, dicha célula inmune diseñada comprende además un receptor de antígeno genéticamente diseñado que se une específicamente a un antígeno objetivo; la presente invención también se refiere a un método para obtener una célula inmune diseñada genéticamente que comprende un paso que consiste en inhibir la expresión y/o actividad de Suv39h1 en la célula inmune; y opcionalmente comprende además un paso que consiste en introducir en dicha célula inmune un receptor de antígeno genéticamente diseñado que se une específicamente a un antígeno objetivo; la invención también abarca dicha célula inmune diseñada para su uso en terapia adoptiva, notablemente para el tratamiento de cáncer.
MX2019015841A 2017-06-20 2018-06-20 Celulas inmunes defectuosas para suv39h1. MX2019015841A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17305757 2017-06-20
PCT/EP2018/066387 WO2018234370A1 (en) 2017-06-20 2018-06-20 DEFECTIVE IMMUNE CELLS AGAINST SUV39H1

Publications (1)

Publication Number Publication Date
MX2019015841A true MX2019015841A (es) 2020-08-03

Family

ID=59295130

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019015841A MX2019015841A (es) 2017-06-20 2018-06-20 Celulas inmunes defectuosas para suv39h1.
MX2023006039A MX2023006039A (es) 2017-06-20 2019-12-20 Celulas inmunes defectuosas para suv39h1.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023006039A MX2023006039A (es) 2017-06-20 2019-12-20 Celulas inmunes defectuosas para suv39h1.

Country Status (22)

Country Link
US (4) US10576103B2 (es)
EP (2) EP3538645B1 (es)
JP (2) JP7388798B2 (es)
KR (1) KR20200027512A (es)
CN (3) CN114350613A (es)
AU (1) AU2018287042A1 (es)
BR (2) BR112019027133B8 (es)
CA (1) CA3067446A1 (es)
CY (1) CY1124069T1 (es)
DK (1) DK3538645T3 (es)
ES (1) ES2871400T3 (es)
HR (1) HRP20210567T1 (es)
HU (1) HUE053760T2 (es)
IL (1) IL271618B1 (es)
LT (1) LT3538645T (es)
MX (2) MX2019015841A (es)
PL (1) PL3538645T3 (es)
PT (1) PT3538645T (es)
RS (1) RS61691B1 (es)
SG (1) SG11201912455VA (es)
SI (1) SI3538645T1 (es)
WO (1) WO2018234370A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL271618B1 (en) * 2017-06-20 2024-02-01 Inst Curie Immune cells are defective in SUV39H1
EP4003407A1 (en) * 2019-07-23 2022-06-01 Mnemo Therapeutics Immune cells defective for suv39h1
CN116406421A (zh) * 2021-07-13 2023-07-07 苏州沙砾生物科技有限公司 一种免疫细胞的培养方法及其用途
WO2023126458A1 (en) * 2021-12-28 2023-07-06 Mnemo Therapeutics Immune cells with inactivated suv39h1 and modified tcr
WO2023137472A2 (en) * 2022-01-14 2023-07-20 Tune Therapeutics, Inc. Compositions, systems, and methods for programming t cell phenotypes through targeted gene repression
WO2023139269A1 (en) 2022-01-21 2023-07-27 Mnemo Therapeutics Modulation of suv39h1 expression by rnas
EP4279085A1 (en) 2022-05-20 2023-11-22 Mnemo Therapeutics Compositions and methods for treating a refractory or relapsed cancer or a chronic infectious disease
WO2024074713A1 (en) 2022-10-07 2024-04-11 Institut National de la Santé et de la Recherche Médicale Method to generate improving car-t cells

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6566A (en) 1849-07-03 Manufacture of bags and sacks
US131A (en) 1837-02-24 Machine foe cutting eur fedm skins
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4946787A (en) 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5049386A (en) 1985-01-07 1991-09-17 Syntex (U.S.A.) Inc. N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
AU7979491A (en) 1990-05-03 1991-11-27 Vical, Inc. Intracellular delivery of biologically active substances by means of self-assembling lipid complexes
US5487994A (en) 1992-04-03 1996-01-30 The Johns Hopkins University Insertion and deletion mutants of FokI restriction endonuclease
US5356802A (en) 1992-04-03 1994-10-18 The Johns Hopkins University Functional domains in flavobacterium okeanokoites (FokI) restriction endonuclease
US5436150A (en) 1992-04-03 1995-07-25 The Johns Hopkins University Functional domains in flavobacterium okeanokoities (foki) restriction endonuclease
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
DE19608753C1 (de) 1996-03-06 1997-06-26 Medigene Gmbh Transduktionssystem und seine Verwendung
US6451995B1 (en) 1996-03-20 2002-09-17 Sloan-Kettering Institute For Cancer Research Single chain FV polynucleotide or peptide constructs of anti-ganglioside GD2 antibodies, cells expressing same and related methods
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
US6566131B1 (en) 2000-10-04 2003-05-20 Isis Pharmaceuticals, Inc. Antisense modulation of Smad6 expression
EP1109921A4 (en) 1998-09-04 2002-08-28 Sloan Kettering Inst Cancer FOR PROSTATE-SPECIFIC MEMBRANE-ANTI-SPECIFIC FUSION RECEPTORS AND THEIR USE
US6410323B1 (en) 1999-08-31 2002-06-25 Isis Pharmaceuticals, Inc. Antisense modulation of human Rho family gene expression
US6410319B1 (en) 1998-10-20 2002-06-25 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
US6107091A (en) 1998-12-03 2000-08-22 Isis Pharmaceuticals Inc. Antisense inhibition of G-alpha-16 expression
US5981732A (en) 1998-12-04 1999-11-09 Isis Pharmaceuticals Inc. Antisense modulation of G-alpha-13 expression
US6046321A (en) 1999-04-09 2000-04-04 Isis Pharmaceuticals Inc. Antisense modulation of G-alpha-i1 expression
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
WO2001068836A2 (en) 2000-03-16 2001-09-20 Genetica, Inc. Methods and compositions for rna interference
EP1287357A2 (en) 2000-06-02 2003-03-05 Memorial Sloan-Kettering Cancer Center Artificial antigen presenting cells and methods of use thereof
US6365354B1 (en) 2000-07-31 2002-04-02 Isis Pharmaceuticals, Inc. Antisense modulation of lysophospholipase I expression
US6566135B1 (en) 2000-10-04 2003-05-20 Isis Pharmaceuticals, Inc. Antisense modulation of caspase 6 expression
DE60122765D1 (de) 2000-11-07 2006-10-12 Hope City Cd19-spezifische umgezielte immunzellen
US7070995B2 (en) 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
US20090257994A1 (en) 2001-04-30 2009-10-15 City Of Hope Chimeric immunoreceptor useful in treating human cancers
US20030170238A1 (en) 2002-03-07 2003-09-11 Gruenberg Micheal L. Re-activated T-cells for adoptive immunotherapy
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
US20050129671A1 (en) 2003-03-11 2005-06-16 City Of Hope Mammalian antigen-presenting T cells and bi-specific T cells
US20050025763A1 (en) 2003-05-08 2005-02-03 Protein Design Laboratories, Inc. Therapeutic use of anti-CS1 antibodies
AU2005235811B2 (en) 2004-02-06 2011-11-03 Morphosys Ag Anti-CD38 human antibodies and uses therefor
US20090304679A1 (en) 2004-05-27 2009-12-10 Weidanz Jon A Antibodies as T cell receptor mimics, methods of production and uses thereof
DK2567976T3 (en) 2005-03-23 2017-10-23 Genmab As ANTIBODIES AGAINST CD38 FOR TREATMENT OF MULTIPLE MYLOMA
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
HUE038506T2 (hu) 2007-03-30 2018-10-29 Memorial Sloan Kettering Cancer Center Kostimuláló ligand konstitutív expressziója adoptív módon átvitt T-limfocitákon
US8479118B2 (en) 2007-12-10 2013-07-02 Microsoft Corporation Switching search providers within a browser search box
KR101626416B1 (ko) 2007-12-26 2016-06-01 바이오테스트 아게 Ｃｄ138 표적 물질 및 이의 용도
WO2009126537A1 (en) * 2008-04-07 2009-10-15 Syndax Pharmaceuticals, Inc. Administration of an inhibitor of hdac and an hmt inhibitor
JP5173594B2 (ja) 2008-05-27 2013-04-03 キヤノン株式会社 管理装置、画像形成装置及びそれらの処理方法
TWI580431B (zh) 2008-08-19 2017-05-01 腫瘤療法 科學股份有限公司 Ｈｉｇ２與ｕｒｌｃ１０抗原決定位胜肽以及含此胜肽之疫苗
JP2012507555A (ja) 2008-10-31 2012-03-29 アボット バイオセラピューティクス コーポレイション 稀少疾患の治療における抗ｃｓ１抗体の使用
WO2011009173A1 (en) 2009-07-23 2011-01-27 Mater Medical Research Institute Cancer immunotherapy
EP2510096B2 (en) 2009-12-10 2018-02-07 Regents of the University of Minnesota Tal effector-mediated dna modification
CN103025344B (zh) 2010-05-17 2016-06-29 桑格摩生物科学股份有限公司 新型dna-结合蛋白及其用途
DK2649086T3 (en) 2010-12-09 2017-09-18 Univ Pennsylvania USING CHEMICAL ANTIGEN RECEPTOR-MODIFIED T-CELLS TO TREAT CANCER
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
RU2688185C2 (ru) 2011-03-23 2019-05-21 Фред Хатчинсон Кэнсер Рисерч Сентер Способ и композиции для клеточной иммунотерапии
EA201391449A1 (ru) 2011-04-01 2014-03-31 Мемориал Слоан-Кеттеринг Кэнсер Сентер Антитела против пептидов цитозоля
US8398282B2 (en) 2011-05-12 2013-03-19 Delphi Technologies, Inc. Vehicle front lighting assembly and systems having a variable tint electrowetting element
US9943536B2 (en) * 2011-10-03 2018-04-17 Universite Libre De Bruxelles Reactivation of HIV-1 gene expression to treat persistent HIV infection
WO2013050405A1 (en) * 2011-10-03 2013-04-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of th2 mediated diseases
EP2776451B1 (en) 2011-11-11 2018-07-18 Fred Hutchinson Cancer Research Center Cyclin a1-targeted t-cell immunotherapy for cancer
EP3594245A1 (en) 2012-02-13 2020-01-15 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
WO2013126726A1 (en) 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Double transgenic t cells comprising a car and a tcr and their methods of use
NZ702108A (en) 2012-05-03 2016-09-30 Hutchinson Fred Cancer Res Enhanced affinity t cell receptors and methods for making the same
KR102437522B1 (ko) 2012-05-25 2022-08-26 셀렉티스 면역요법을 위한 동종이형 및 면역억제제 저항성인 ｔ 세포의 조작 방법
WO2014031687A1 (en) 2012-08-20 2014-02-27 Jensen, Michael Method and compositions for cellular immunotherapy
US9181535B2 (en) 2012-09-24 2015-11-10 The Chinese University Of Hong Kong Transcription activator-like effector nucleases (TALENs)
CN104853766A (zh) 2012-10-02 2015-08-19 纪念斯隆-凯特琳癌症中心 用于免疫疗法的组合物和方法
EP3763810A3 (en) 2012-10-10 2021-07-14 Sangamo Therapeutics, Inc. T cell modifying compounds and uses thereof
JP6465803B2 (ja) 2012-10-22 2019-02-06 シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ Ｅｔｐ誘導体
US20140161785A1 (en) * 2012-12-10 2014-06-12 Feiyan Liu Verticillin A Inhibition of Histone Methyltransferases
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
WO2014097442A1 (ja) 2012-12-20 2014-06-26 三菱電機株式会社 車載装置及びプログラム
US9108442B2 (en) 2013-08-20 2015-08-18 Ricoh Company, Ltd. Image forming apparatus
MA42895A (fr) 2015-07-15 2018-05-23 Juno Therapeutics Inc Cellules modifiées pour thérapie cellulaire adoptive
IL271618B1 (en) * 2017-06-20 2024-02-01 Inst Curie Immune cells are defective in SUV39H1

Also Published As

Publication number Publication date
US20200171090A1 (en) 2020-06-04
MX2023006039A (es) 2023-06-02
SG11201912455VA (en) 2020-01-30
IL271618B1 (en) 2024-02-01
KR20200027512A (ko) 2020-03-12
LT3538645T (lt) 2021-04-26
US11622978B2 (en) 2023-04-11
JP2024023299A (ja) 2024-02-21
BR112019027133A2 (pt) 2020-07-07
BR112019027133B8 (pt) 2022-08-09
US10576103B2 (en) 2020-03-03
JP2020523995A (ja) 2020-08-13
RU2020101755A (ru) 2021-07-20
ES2871400T3 (es) 2021-10-28
EP3828264A1 (en) 2021-06-02
HUE053760T2 (hu) 2021-07-28
PL3538645T3 (pl) 2021-11-08
IL271618A (en) 2020-02-27
US20190365807A1 (en) 2019-12-05
CN114350613A (zh) 2022-04-15
RS61691B1 (sr) 2021-05-31
CN110997902B (zh) 2021-11-30
AU2018287042A1 (en) 2020-02-06
ES2871400T8 (es) 2022-03-31
EP3538645B1 (en) 2021-01-20
HRP20210567T1 (hr) 2021-09-03
CN114058590A (zh) 2022-02-18
SI3538645T1 (sl) 2021-08-31
BR122020025496B8 (pt) 2023-10-24
CA3067446A1 (en) 2018-12-27
WO2018234370A1 (en) 2018-12-27
PT3538645T (pt) 2021-04-15
DK3538645T3 (da) 2021-04-19
CN110997902A (zh) 2020-04-10
US11285176B2 (en) 2022-03-29
EP3538645A1 (en) 2019-09-18
RU2020101755A3 (es) 2021-08-16
JP7388798B2 (ja) 2023-11-29
CY1124069T1 (el) 2022-05-27
BR122020025496B1 (pt) 2023-09-26
US20230201264A1 (en) 2023-06-29
US20220040235A1 (en) 2022-02-10
BR112019027133B1 (pt) 2022-07-19

Similar Documents

Publication Publication Date Title
MX2023006039A (es) Celulas inmunes defectuosas para suv39h1.
NZ765695A (en) Immune cell organoid co-cultures
MX2020005634A (es) Composiciones y metodos para mejorar los linfocitos infiltrantes de tumor para terapia celular adoptiva.
EP3964527A3 (en) Combination therapy for cancer
MX2018010473A (es) Terapia de combinacion con anticuerpos anti cumulo de diferenciacion 73 (cd73).
PH12018500380A1 (en) Anti-dll3 antibody drug conjugates and methods of use
GB2557123A (en) Modified cells and methods of therapy
JOP20190283B1 (ar) طريقة لتصنيع أجسام مضادة ثنائية النوعية، والأجسام المضادة ثنائية النوعية والاستخدام العلاجي لها
NZ750974A (en) Antibody and checkpoint inhibitor combination therapy
MY189028A (en) Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
MX2017005553A (es) Terapia de combinacion para cancer.
MX341076B (es) Formulaciones estables de anticuerpos para el receptor humano pd-1 de meurte programada y tratamientos relacionados.
MX2021006734A (es) Metodo para tratar el cancer.
WO2015200828A8 (en) Conjugates for immunotherapy
PH12016501976A1 (en) Antibodies, pharmaceutical compositions and uses thereof
EA201400625A1 (ru) Антитела против pd-l1 и их применение
MX2019000286A (es) Una combinación farmacéutica y método para la regulación del microentorno tumoral e inmunoterapia.
MX2017006167A (es) Compuestos que interactúan con glicanos y métodos de uso.
MX2018002344A (es) Metodo para tratar el cancer.
MX2019010382A (es) Metodo de tratamiento de tumor inmunoterapeutico utilizando un agonista alfa,beta-selectivo del receptor de interleuquina-2 en combinacion con terapia de transferencia celular adoptiva.
WO2019090347A8 (en) Adenosine pathway inhibitors for cancer treatment
MX2018006249A (es) Nuevos anticuerpos anti-emr2 y metodos de uso.
PH12021551036A1 (en) Anti-liv1 immune cell cancer therapy
MX2022002682A (es) Anticuerpos anti-cd73.
MX2021013368A (es) Celulas t del receptor de antigenos quimericos focalizadas a cd19 especificas del antigeno.